Ipsen: Barclays downgrades stock

(CercleFinance.com) - Barclays has downgraded its rating on the Ipsen share from "overweight" to "weight in line" and has cut its corresponding target price from 130 euros to 90 euros, highlighting unfavourable news about palovarotene that was published late last week.


"Whilst we still see a longer-term positive path for IPN, we expect that the now added uncertainty with palo will again amplify Somatuline sustainability issues," the broker warns.

Barclays therefore believes that the Ipsen share will have difficulty attracting additional investors until clarification is obtained on at least one (if not all) of these issues.


Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.